Cadila settles litigation with Celgene over patents for the anti-cancer drug Revlimid
Cadila Healthcare and its subsidiary Zydus Pharmaceuticals Inc. have reached a settlement with Celgene Corporation on 24 March 2021. This settlement was done over the patents for the anti–cancer drug Revlimid.
Per this agreement, both parties will file consent judgments with the US district court for New Jersey. This will prohibit Zydus Cadila from marketing the generic version of the drug before the patent expires, except as provided for in the settlement. [3]
About Revlimid
Revlimid is used for the treatment of multiple myeloma and myelodysplastic syndrome. Its patent expires in March 2022. US–based firm Celgene Corporation is a wholly–owned subsidiary of Bristol Meyers Squibb ( BMS ). In 2020, BMS had garnered over $ 12 billion in sales from Revlimid, making it the largest drug in its sales in 2020.
Cadila is apparently the fifth company to settle litigation with Celgene over the patent. The other companies that were previously involved were Cipla, Natco Pharma, and Dr. Reddy’s Laboratories. A few pharma firms are still locked in legal battles with this US–based firm. These include Aurobindo Pharma, Hetero Drugs, Mylan, Sun Pharma, and Lupin.
Cipla had resolved its case with Celgene in December 2020. Based on the agreement, Cipla would get a license to manufacture and sell a certain volume of the generic version in the US after March 2022. Apart from this, until 31 January 2026, the volume of generic Revlimid sold by Cipla could not exceed the agreed–upon percentages. After this period, Cipla can manufacture and sell an unlimited quantity of the drug.
- Pharma News August 2021GC Pharma and Tottori University have collaborated to accelerate the global development of the chaperone therapy of GM1 gangliosidosis (GM1). …
- Monthly Update- pharma News July 2021
pharma News July 2021: Let us know what’s happening around the globe and the Indian Pharma Industry. Three-dose ZyCoV-D vaccine … - Moderna collaborates with Thermo Fischer Scientific
Moderna collaborates with Thermo Fischer Scientific to ramp up its COVID – 19 vaccine production Moderna Inc had entered into …Moderna collaborates with Thermo Fischer Scientific Read More »
- Bamlanivimab and Etesevimab: EUA in India
On 2 June 2021, the antibody-drug combination by the US drugmaker Eli Lilly was granted EUA[1] in India. This combination … - JB Chemicals launches NOSMOK nicotine lozenges
JB Chemicals & Pharma launches NOSMOK nicotine lozenges to help with smoking cessation : On 31 May 2021, JB Chemicals … - 2-DG: anti-COVID-19 by the INMAS
Dr. Reddy’s to charge Rs. 990 for each sachet of the anti-COVID-19 medicine by DRDO (2-DG) Dr. Reddy’s has recently …